UpDate - Vol. 12, No. 4, Page 1                                
September 24, 1992                                             
Research aims to reduce heart disease, infant death            
                                                               
     Two Delaware researchers-with support from the American Heart   
Association (AHA) of Delaware Inc.-are conducting research that may  
lead to a better medical understanding of the Sudden Infant Death    
Syndrome (SIDS) and to enhanced treatment of those at risk of heart  
disease and stroke.                                                  
     David Usher, associate professor of life and health sciences, and        
Harold White, professor of chemistry and biochemistry, each have     
received a $20,000 grant from the AHA for 1992-93.                   
                                                               
Ushering in another risk factor                                      
     Usher's research is focused on lipoprotein (a), or Lp(a), a type
of cholesterol-carrying particle that interferes with the ability to 
dissolve clots formed in damaged arteries as part of the body's repair        
mechanisms.                                                          
     According to Usher, cholesterol is a necessary element in the   
diet, to form membranes as new cells develop, and for synthesizing   
hormones such as adrenalin and sex hormones. However, when too much  
cholesterol is present, it begins to build up, causing damage to blood        
vessels.                                                             
     Clots that are formed when blood vessels are damaged can be     
dissolved by the blood protein, plasminogen. Lp(a), however, seems to
prevent plasimogen from dissolving clots, which accelerates the      
blockage of arteries, causing cardiovascular disease. This process may        
go on for years before problems emerge, Usher said.                  
     Lp(a) was discovered 25 years ago, but only recently is it
thought to be linked to arteriosclerosis or clogging of arteries. In 
previous research, Usher has developed a clinical test for Lp(a),    
which is used in Europe and Japan, and is awaiting approval by the   
Federal Drug Adminstration. Those who have a significant amount in   
their bloodstreams have six-times the risk of heart attack, some     
researchers believe. It is thought that the amount of Lp(a) in the   
bloodstream is genetically controlled, Usher said                    
     Lp(a) molecules vary in size in different individuals, with some
carrying heavy particles and some light. Oddly enough, it is persons 
with the light particles that seem most at risk, while those with    
heavy particles are less so, Usher said.                             
     Usher's research examines these heavy and light Lp(a) molecules,
using enzymes that cut proteins to study their structure and to      
determine differences in their structure and function and how their  
size relates to the ability of the particles to bind to clots, leading        
to blockage.                                                         
     "Understanding Lp(a) in relation to heart disease and stroke may   
lead to better treatments of those at risk," Usher said.             
     Usher also is a co-investigator in another AHA-funded project   
with Michael Spear, a physician who heads neonatology at the Delaware
Medical Center.                                                      
     Premature babies are fed fats intravaneously in order to survive.        
Some infants form an abnormal type of lipoprotein and cannot seem to 
remove these lipoproteins from their bodies.                         
     By taking periodic blood samples and analyzing these samples over        
a period of time, it is hoped to discover what changes are taking    
place in the blood lipoproteins of these infants.                    
                                                               
The white of the egg                                                 
     White is conducting research on embryonic distress in chickens, 
which may provide insights into human Sudden Infant Death Syndrome   
(SIDS). "The heartbeat of a chick embryo is so difficult to detect   
that a heart monitor that amplifies the sound a half million times   
must be attached to the egg to record it," he said.                  
     White studies fertilized eggs that lack riboflavin, or Vitamin  
B2, because of a genetic defect in the research hens that lay them.  
Without this essential vitamin, the chicken embryos die approximately
13 days after fertilization, instead of hatching in the usual 21 days.        
     For his research, it is important to monitor the embryos and to 
study the onset and progress of heart dysfunction and determine      
precisely the time of death. For this purpose, he uses a miniature   
microphone (heart monitor), which feeds information into a computer. 
     White currently has one monitor, and the AHA grant will enable     
him to design and build 16 monitors to study the hearts of several   
embryos simultaneously. One of White's related research goals is to  
further the development of such sophisticated heart monitors.        
     The computer analysis of an embryo heart resembles a miniature  
EKG, showing a sharp dip when the heart ceases to function and the   
embryo dies. By comparing these print-outs, White looks for consistent        
signs of the onset of embryonic distress. He also compares these     
riboflavin deficient eggs with viable eggs from the same flock that  
have received ribloflavin injections                                 
     "The heart is a muscle," White said, "and it requires oxygen to 
function. If there is no riboflavin, an inability to use oxygen occurs        
and the heart stops.                                                 
     While no SIDS deaths have been linked to riboflavin deficiency, 
there are some metabolic similarities between the rapidly developing 
chicken embryo and infants at the age when most SIDS deaths occur,   
White said.                                                          
     In a summary of his research, White wrote, "While we find our      
specific scientific research on the biochemistry of riboflavin most  
interesting, the greatest impact of this work may well be its        
unforeseen influence on other research areas that could use a heart  
monitor.                                                             
     "Sydney Brenner once said, 'Progress in science depends on new  
techniques, new discoveries and new ideas, probably in that order.'  
Certainly we hope that the major effect of our work will be on the new        
work that it makes possible in this and other laboratories," White   
wrote.                                                               
                                        -Sue Swyers Moncure